

Sample content

Non-Small-Cell Lung Cancer

China In-Depth

About China In-Depth

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



How can we optimize long-term disease and development strategy in China?



What are the current treatment paradigms for non-small-cell lung cancer?



What is the access and reimbursement environment for non-small-cell lung cancer in China?



What is the market potential of our pipeline assets and those of our competitors?



What is the current and future therapeutic landscape for non-small-cell lung cancer in China?



What is the commercial outlook and impact of key market events?

Report coverage

Geography



China

Market forecast

Forecast: 10-year, annualized, drug-level sales and patient shares of key NSCLC regimens through 2034, based on primary and secondary market research to formulate bottom-up assumptions.


Epidemiology: Total diagnosed incident cases of NSCLC in both urban and rural China. Clinically and market-relevant drug-treatable populations.


Primary market research

Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 oncologists in China

Report format

 PPT with analyses and key takeaways

 **Market Forecast Assumptions** (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)

 **Market Forecast Dashboard** (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)




Key therapies included in the analysis

Drug / regimen	Manufacturer
Pembrolizumab (Keytruda)	Merck
Osimertinib (Tagrisso)	AstraZeneca
Furmonertinib (AiFuSha)	Allist Pharma
Bevacizumab (Avastin)	Roche; biosimilars
Ivonescimab (Yidafang)	Akeso
Benmelstobart (TQB2450)	CTTQ
Alectinib (Alecensa)	Roche
Trastuzumab deruxtecan (Enhertu)	AstraZeneca / Daiichi Sankyo
Datopotamab Deruxtecan	AstraZeneca
Aumolertinib (Ameile)	Hansoh Pharma
Lorlatinib (Lorbrena)	CStone/Pfizer
Durvalumab (Imfinzi)	AstraZeneca
Sintilimab (Tyvyt)	Innovent

Question answered

What are the expected sales of key drugs used to treat non-small-cell lung cancer in the China over the next 10 years?


Sales of top current therapies for NSCLC in China: 2024-2034



Question answered

What are the expected sales of non-small-cell lung cancer emerging therapies in China over the next 10 years?

Sales of emerging therapies for NSCLC in China: 2024-2034



Question answered

Who are the key drug developers in this market?

Top 5 MNCs



Leading brands

Tagrisso, Imfinzi
Keytruda and Toposider
Abraxa, Risperdal and Tazace
Cosentyx, Kadcycla and Vioxx
Talisman, Zylmar, Talcid and Makenzie

Top 5 domestic developers



Leading brands

ADPultra
Compassion/Biomax
Atracis
Fyopt
Bioscience

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?





About Clarivate

Disease Intelligence and Analytics

Disease intelligence you can trust



Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:

clarivate.com/products/biopharma/portfolio-strategy-business-development



Think forward™

Contact our experts today:

lsh.support@clarivate.com

clarivate.com

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.